Jazz Pharmaceuticals completed its $820 million acquisition of Actio Biosciences, gaining ABS-1230, a promising oral precision therapy for KCNT1-related epilepsy. ABS-1230 has shown potential in early trials to reduce seizures in children and holds multiple FDA designations, signaling accelerated development. This acquisition strengthens Jazz's rare disease pipeline and commitment to innovative epilepsy treatments. Jazz plans to rapidly advance ABS-1230 through clinical development and regulatory processes.
Jazz Pharmaceuticals' acquisition of Actio Biosciences provides context for readers. For those following the health sector, here is Pluang's market snapshot as of Sep 15, 2026 19:14 WIB: out of 91 priced US health stocks, 28 rose and 59 fell. Notable movers include Aurora Cannabis Inc (ACB) at USD 3.92 with a +2.89% change and Inovio Pharmaceuticals Inc (INO) at USD 1.21 with a +2.54% change.
DelveInsight's 2026 report highlights more than 100 BCMA-targeted therapies in various clinical stages, focusing on multiple myeloma and other diseases. Leading pharma companies like Pfizer, Regeneron, and AstraZeneca are advancing treatments includi...
Timeplast, a materials company with over 9,000 customers, has launched a Regulation A+ offering open to the public to license its patented water-soluble plastic technology. This plastic dissolves in water after a programmed period, reducing plastic w...
D.A. Davidson raised Riskified's price target to $12, reflecting a 22.2% potential upside from $9.82. The company reported a 41% revenue increase to $115.2 million and adjusted earnings of $0.07 per share, beating estimates. Profitability improved wi...
TRM Labs introduced the Disruption Awards to recognize coalitions of public and private organizations that successfully disrupted major cybercrimes in 2026. Winners include groups that took down a phishing service responsible for most Microsoft-block...
Existing-home sales in the U.S. dropped 5.5% month-over-month and 8.8% year-over-year in October, reaching the lowest level since August 2010. The decline is attributed to mortgage rates rising to their highest since 2000, making home buying more dif...
